Axillary Lymph Node Status and neoadjuvant Therapy in HER2-positive Breast Carcinoma

被引：0
|
作者：
Danzinger, S. [1 ]
Pfeifer, C. [2 ]
Wimmer, S. [1 ]
Tendl-Schulz, K. [3 ]
Singer, C. F. [1 ]
机构：
[1] Med Univ Wien, Univ Klin Frauenheilkunde, Vienna, Austria
[2] Univ Innsbruck, Inst Stat, Innsbruck, Austria
[3] Med Univ Wien, Klin Inst Pathol, Vienna, Austria
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2023年 / 83卷 / 04期
关键词：
D O I：
10.1055/s-0043-1766396
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
005
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [41] Sentinel Lymph Node Detection In Patients With Breast Cancer And Positive Axillary Lymph Node After Neoadjuvant Chemotherapy
    Carcamo-Ibarra, P.
    Rodriguez-Parra, H.
    Redal-Pena, M.
    Casans-Tormo, I.
    Carrero-Vasquez, V.
    Canoves-Llombart, A.
    Sabater-Sancho, J.
    Lopez-Gonzalez, U.
    Soria-Merino, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S611 - S611
  • [42] Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Carcinoma of the Breast
    Schwartz, Gordon F.
    Tannebaum, Jonathan E.
    Jernigan, Amelia M.
    Palazzo, Juan P.
    CANCER, 2010, 116 (05) : 1243 - 1251
  • [43] Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
    Mou, Exian
    Ji, Juan
    Liu, Shiwei
    Shu, Lan
    Zou, Liqun
    Li, Zhuoxuan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [44] Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
    Shin, Junyoung
    Ham, Baknoon
    Seo, Jeong-Han
    Lee, Sae Byul
    Park, In Ah
    Gong, Gyungyub
    Kim, Sung-Bae
    Lee, Hee Jin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [45] HER2-positive Breast Cancer: MRI-based Optimization of Neoadjuvant Therapy
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 666 - 666
  • [46] Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
    Bischoff, Herve
    Espie, Marc
    Petit, Thierry
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, : 1225 - 1237
  • [47] Use of MammaTyper® in predicting response to neoadjuvant therapy in HER2-positive breast cancer
    Scatena, C.
    Belcastro, E.
    Marletta, S.
    Tornabene, I.
    Cinacchi, P.
    Fontana, A.
    Martorana, F.
    Vigneri, P.
    Rizzo, A.
    Naccarato, A. G.
    BREAST, 2025, 80 : S78 - S79
  • [48] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [49] Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
    Guiu, S.
    Reynier, M. A. Mouret
    Toure, M.
    Coudert, B.
    JOURNAL OF ONCOLOGY, 2013, 2013
  • [50] Topoisomerase II-alpha gene status and pathologic response to neoadjuvant chemotherapy in HER2-Positive breast carcinoma
    Peiro, G.
    Aranda, F. I.
    Adrover, E.
    Peiro, F. M.
    Abuomar, A.
    Niveiro, M.
    Benlloch, S.
    LABORATORY INVESTIGATION, 2007, 87 : 45A - 45A
12345